A seizure in the confined environment of an aircraft can transform an otherwise routine flight into a rapidly evolving medical emergency, forcing cabin crew and volunteer clinicians to make decisions with limited equipment, incomplete medical histories and no immediate access to hospital care. A new Viewpoint in JAMA Neurology argues that benzodiazepines deserve serious consideration for inclusion in airline emergency medical kits, particularly because these drugs can interrupt prolonged or recurrent seizures before they cause life-threatening complications. The authors emphasize, however, that adding a medication to an aircraft kit is not simply a matter of placing it in a box. The decision requires careful evaluation of drug selection, route of administration, crew training, passenger safety, legal responsibilities and the practical limitations of treating a neurological emergency thousands of feet above the ground.
Most seizures end spontaneously within a few minutes, and immediate supportive care is often sufficient. The priority is to protect the person from injury, place them in a safe position when possible, remove nearby hazards and avoid restraining them or placing objects in their mouth. A seizure becomes more concerning when convulsive activity continues for approximately five minutes or when seizures recur without recovery of consciousness between episodes. This situation may represent convulsive status epilepticus, a neurological emergency associated with impaired breathing, oxygen deprivation, metabolic disturbances, physical injury and the risk of permanent brain damage or death. Benzodiazepines are established first-line treatments for stopping prolonged seizures because they enhance the activity of gamma-aminobutyric acid, or GABA, the brain’s principal inhibitory neurotransmitter.
By increasing GABA-mediated inhibition, benzodiazepines reduce the excessive electrical activity that drives a seizure. Their effectiveness is time-sensitive: as a seizure continues, the brain can become progressively less responsive to some medications, making rapid administration increasingly important. In a hospital, clinicians may administer intravenous lorazepam or diazepam, while intramuscular midazolam is commonly used when intravenous access is difficult. For an aircraft, injectable drugs may be less practical because they require equipment, preparation, technical skill and a person capable of safely identifying the correct dose and route. Nonintravenous formulations, including intranasal or buccal midazolam and rectal diazepam, could offer operational advantages because they can be delivered more quickly and without establishing an intravenous line, although each option carries different storage, training and acceptability considerations.
The case for carrying benzodiazepines in airline medical kits is strengthened by the distinctive medical environment of commercial aviation. Aircraft cabins provide limited space, restricted privacy and only basic monitoring compared with an emergency department. A passenger experiencing a seizure may be surrounded by frightened travelers, while cabin crew must simultaneously preserve safety, communicate with ground-based medical support and determine whether diversion to the nearest airport is necessary. Oxygen may be available, but advanced airway equipment, continuous cardiorespiratory monitoring and personnel experienced in managing status epilepticus may not be. A medication capable of stopping a seizure before the aircraft lands could potentially reduce the duration of convulsions and the risk of complications, particularly on long-haul flights or routes far from suitable diversion airports.
The same pharmacological properties that make benzodiazepines useful also create risks that cannot be ignored. Excessive sedation can impair consciousness and make it difficult to assess the passenger’s neurological status. Benzodiazepines can suppress breathing, especially when administered inappropriately, in excessive doses or to people who have also consumed alcohol, opioids or other sedating substances. A person who appears to be having a seizure may instead have fainted, experienced a cardiac rhythm disturbance, suffered a low blood sugar episode or developed another condition requiring different treatment. Even when the diagnosis is correct, a drug may not completely stop the seizure, and additional therapy could be needed after landing. Any aviation protocol would therefore need to pair medication access with clear criteria for use and robust support for airway and breathing management.
The formulation selected for an airline kit would have to reflect the realities of emergency care in the cabin. An intranasal preparation could be administered without needles and may be easier for trained personnel to use, but nasal congestion, bleeding or incorrect positioning could reduce absorption. Buccal administration can also avoid injection, yet it requires access to the mouth and may be difficult during forceful convulsions or excessive secretions. Rectal administration is an established option in some settings but may be unacceptable to passengers and challenging in a crowded aircraft. Injectable preparations may be familiar to medical professionals but pose additional risks if used by people without appropriate training. The Viewpoint presents these considerations as part of a broader systems question rather than endorsing one universal medication or delivery method for every airline.
Training and governance could determine whether the presence of benzodiazepines improves outcomes or introduces new hazards. Cabin crew would need to know how to recognize a seizure, distinguish prolonged convulsions from normal post-seizure unresponsiveness and protect themselves and the passenger during administration. They would also need instruction on when not to give the medication, how to summon medical assistance, how to record the timing and dose, and how to monitor breathing afterward. A physician or other qualified health professional traveling as a passenger might provide assistance, but relying on a volunteer’s presence is unpredictable. Airlines would have to establish protocols that clarify who is authorized to administer the drug, how remote medical direction is obtained and what documentation follows the event.
The logistical challenges extend beyond clinical decisions. Benzodiazepines are controlled substances in many jurisdictions, creating requirements for procurement, storage, inventory control and disposal. Airline operators would need to account for security, theft prevention, medication expiration, temperature exposure, international regulations and the differences among national aviation authorities. Emergency kits already vary by airline, aircraft type and route, and the addition of a prescription medication could affect costs and regulatory obligations. At the same time, omitting benzodiazepines may leave crews dependent on supportive care during a condition in which every minute can matter. The authors frame this tension as a need for evidence-based policy, standardized protocols and collaboration among neurologists, emergency physicians, aviation regulators, airlines, pharmacists and patient advocates.
The Viewpoint does not report a new clinical trial or establish that carrying benzodiazepines on every commercial flight will prevent deaths or reduce diversions. Instead, it draws attention to an underexamined gap between modern seizure treatment and the capabilities available during air travel. Further work could examine how often prolonged seizures occur on commercial flights, which formulations are most practical, how frequently trained medical professionals are available onboard, and whether medication access changes outcomes without increasing adverse events. Until those questions are addressed, the central message is one of preparedness: airlines should evaluate seizure care as part of their emergency planning, while recognizing that a drug is only one component of a safe response. For passengers with epilepsy, the discussion may also reinforce the importance of carrying prescribed rescue medication, informing travel companions about an individualized seizure action plan and following medical advice before flying.
Subject of Research: The inclusion of benzodiazepines in airline emergency medical kits for the treatment of prolonged or recurrent seizures during flight.
Web References: https://doi.org/10.1001/jamaneurol.2026.2787
References: Sirven JI. Viewpoint on the importance and considerations of including benzodiazepines in airline emergency medical kits. JAMA Neurology. doi:10.1001/jamaneurol.2026.2787.
Keywords: benzodiazepines, seizures, epilepsy, status epilepticus, airline medicine, in-flight medical emergencies, emergency medical kits, midazolam, neurological emergencies, aviation safety
Tags: airline emergency medical kitsairline medical emergency preparednessbenzodiazepines for seizure managementcabin crew medical training for seizuresemergency response to prolonged seizures on planesin-flight medication protocolsin-flight neurological emergency treatmentinclusion of benzodiazepines in airline medical kitslegal considerations for in-flight medicationspractical challenges of treating neurological emergencies at high altitudesafety protocols for passenger seizuresseizure intervention in aircraft
